STOCKS IN ACTION 5 June

SBI CARDS AND PAYMENT SERVICES
: Boardmeet Today
To Consider Raising of Funds Via NCDs aggregating Rs 3000 Crores

MUTHOOT CAPITAL SERVICES: Board to meet on June-7
To consider and approve fund raising by way of issuance of Non-Convertible Debentures (NCDs) on Private Placement basis

SAMVARDHANA MOTHERSON INTERNATIONAL: Completed acquisition of additional 30% stake of Youngshin Motherson Auto Tech Limited from Youngshin Components Co. Ltd., Korea

MINDA CORPORATION: Board considered and approved the proposal of raising of funds by way of further issuance of securities through public and/or private offerings including preferential issue, QIP, FPO, for an aggregate amount not exceeding Rs 600 Crores

ZYDUS LIFESCIENCES: Group’s animal health drug manufacturing facility at SEZ, Ahmedabad underwent a USFDA inspection from 30th May to 2nd June, 2023
The inspection closed with NIL observations

BIOCON: US FDA concluded a surveillance and pre-approval inspection of Biocon Pharma Limited Oral Solid Dosage formulations manufacturing facility at Bengaluru on 2nd June 2023, with no observations

LUPIN: Announced the launch of Darunavir Tablets, 600 mg and 800 mg, to market a generic equivalent of Prezista® Tablets of Janssen Products, LP
Darunavir Tablets, 600 mg and 800 mg
Had estimated annual sales of USD 308 million in the US

RAMCO SYSTEMS: Global enterprise software company Ramco Systems announced the inauguration of its wholly owned subsidiary in Qatar, to support and transform the region’s business houses and MNCs in the area of ERP, HR, and payroll

MAHINDRA LIFESPACE DEVELOPERS: Mahindra Industrial Park Chennai, a jv between Mahindra World City Developers & Sumitomo Corporation of Japan, announced that OMRON Healthcare will be launching operations in March 2025

IPCA LABORATORIES: Income Tax Department has carried out survey proceedings at the Company’s offices in Mumbai and at Sikkim manufacturing plants between 30th May, 2023 to 3rd June, 2023

DEEPAK FERTILISERS: Creation of pledge over 43,00,000 equity shares representing 3.41% of the total paid-up share capital by a Promoter Entity

INDOCO REMEDIES: USFDA had inspected Company’s Sterile Facility (Plant II) located at Goa, from Feb 20 to Feb 28
The said Facility had 4 observations in Form 483
USFDA has determined the inspection classification of this Facility as OAI (Official Action Indicated)
 
 
Back to Top